Total Knee Arthroplasty Infiltration Study for Postoperative Analgesia
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT03015532 |
Recruitment Status :
Completed
First Posted : January 10, 2017
Results First Posted : October 27, 2021
Last Update Posted : October 27, 2021
|
- Study Details
- Tabular View
- Study Results
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Postoperative Pain | Drug: HTX-011 Drug: Saline Placebo Drug: Bupivicaine HCl Drug: Ropivacaine | Phase 2 |
Study Type : | Interventional (Clinical Trial) |
Actual Enrollment : | 285 participants |
Allocation: | Randomized |
Intervention Model: | Parallel Assignment |
Masking: | Double (Participant, Outcomes Assessor) |
Primary Purpose: | Treatment |
Official Title: | A Phase 2b, Randomized, Double-Blind, Saline Placebo- and Active-Controlled, Multicenter Study of HTX-011 Via Infiltration for Postoperative Analgesia in Subjects Undergoing Total Knee Arthroplasty |
Actual Study Start Date : | January 13, 2017 |
Actual Primary Completion Date : | April 20, 2018 |
Actual Study Completion Date : | May 16, 2018 |
Arm | Intervention/treatment |
---|---|
Experimental: Cohort 1, Group 1: HTX-011
HTX-011 (bupivacaine/meloxicam), 200 mg/6 mg via instillation
|
Drug: HTX-011
HTX-011 (bupivacaine/meloxicam), via instillation |
Experimental: Cohort 1, Group 2: HTX-011
HTX-011 (bupivacaine/meloxicam), 200 mg/6 mg via injection and instillation (combination)
|
Drug: HTX-011
HTX-011 (bupivacaine/meloxicam), via instillation |
Placebo Comparator: Cohort 1, Group 3: Saline Placebo
Saline placebo via injection
|
Drug: Saline Placebo
Saline placebo via injection |
Active Comparator: Cohort 1, Group 4: Bupivacaine HCI
Bupivacaine HCl without epinephrine, 125 mg via injection
|
Drug: Bupivicaine HCl
Bupivacaine HCl without epinephrine |
Experimental: Cohort 2, Group 1: HTX-011
HTX-011 (bupivacaine/meloxicam), 400 mg/12 mg via instillation
|
Drug: HTX-011
HTX-011 (bupivacaine/meloxicam), via instillation |
Experimental: Cohort 2, Group 2: HTX-011 + Ropivacaine
HTX-011 (bupivacaine/meloxicam), 400 mg/12 mg via instillation; Ropivacaine, 50 mg via injection
|
Drug: HTX-011
HTX-011 (bupivacaine/meloxicam), via instillation Drug: Ropivacaine Ropivacaine, via injection |
Placebo Comparator: Cohort 2, Group 3: Saline Placebo
Saline placebo via injection
|
Drug: Saline Placebo
Saline placebo via injection |
Active Comparator: Cohort 2, Group 4: Bupivacaine HCI
Bupivacaine HCl without epinephrine, 125 mg via injection
|
Drug: Bupivicaine HCl
Bupivacaine HCl without epinephrine |
- Mean Area Under the Curve (AUC) of the NRS-R (Windowed Worst Observation Carried Forward) Pain Intensity Scores [ Time Frame: 48 hours ]Pain intensity scores are assessed using an 11-point Numeric Rating Scale (NRS) (0-10) where 0 represents "no pain" and 10 represents "worst pain imaginable". NRS scores are recorded at rest (NRS-R).
- Mean Area Under the Curve (AUC) of the NRS-R (Windowed Worst Observation Carried Forward) Pain Intensity Scores [ Time Frame: 72 hours ]Pain intensity scores are assessed using an 11-point Numeric Rating Scale (NRS) (0-10) where 0 represents "no pain" and 10 represents "worst pain imaginable". NRS scores are recorded at rest (NRS-R).
- Mean Total Postoperative Opioid Consumption (in Morphine Equivalents) [ Time Frame: 72 hours ]
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years and older (Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Is scheduled to undergo primary unilateral TKA under general anesthesia.
- Has not previously undergone TKA in either knee.
- Has an American Society of Anesthesiologists Physical Status of I, II, or III.
- Is able to demonstrate motor function by performing a timed 20-meter walk unassisted, but with the optional use of a 4-legged walker for balance.
- Female subjects are eligible only if not pregnant, not lactating, not planning to become pregnant during the study, sterile; or using acceptable contraceptives.
Exclusion Criteria:
- Has a planned concurrent surgical procedure (eg, bilateral TKA).
- Has a pre-existing concurrent acute or chronic painful/restrictive physical condition that may require analgesic treatment in the postoperative period for pain.
- Has a contraindication or a known or suspected history of hypersensitivity or idiosyncratic reaction to required study medications.
- Has known or suspected daily use of opioids for 7 or more consecutive days within the previous 6 months.
- Has taken NSAIDs within 10 days prior to the scheduled surgery.
- Has taken opioids within 24 hours prior to the scheduled surgery (3 days for long-acting).
- Has been administered bupivacaine within 5 days prior to the scheduled surgery.
- Has initiated treatment with medications within 1 month prior to study drug administration that can impact pain control.
- Has been administered systemic steroids within 5 half-lives or 10 days prior to administration of study drug.
- Has a medical condition such that, in the opinion of the Investigator, participating in the study would pose a health risk to the subject or confound the postoperative assessments.
- Has a known history of Hepatitis B, human immunodeficiency virus (HIV), or active Hepatitis C.
- Has uncontrolled anxiety, psychiatric, or neurological disorder that might interfere with study assessments.
- Has any chronic neuromuscular deficit of either femoral nerve function or thigh musculature. Has any chronic condition or disease that would compromise neurological or vascular assessments.
- Had a malignancy in the last year, with the exception of non-metastatic basal cell or squamous cell carcinoma of the skin or localized carcinoma in situ of the cervix.
- Has a known or suspected history of drug abuse, a positive drug screen on the day of surgery, or a recent history of alcohol abuse.
- Received an investigational product or device in a clinical trial within 30 days or within 5 elimination half lives.
- Has undergone 3 or more surgeries within 12 months.
- Has a body mass index (BMI) >38 kg/m2.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03015532
United States, Alabama | |
Mobile, Alabama, United States, 36608 | |
Sheffield, Alabama, United States, 35660 | |
United States, Arizona | |
Phoenix, Arizona, United States, 85015 | |
Phoenix, Arizona, United States, 85023 | |
United States, California | |
La Jolla, California, United States, 92037 | |
Riverside, California, United States, 92503 | |
San Diego, California, United States, 92103 | |
United States, Florida | |
Miami, Florida, United States, 33136 | |
Miami, Florida, United States, 33143 | |
Miami, Florida, United States, 33155 | |
Tamarac, Florida, United States, 33321 | |
United States, Nevada | |
Las Vegas, Nevada, United States, 89109 | |
United States, Ohio | |
Columbus, Ohio, United States, 43203 | |
Columbus, Ohio, United States, 43210 | |
Dayton, Ohio, United States, 45417 | |
United States, Texas | |
Bellaire, Texas, United States, 77401 | |
Houston, Texas, United States, 77004 | |
Houston, Texas, United States, 77027 | |
Houston, Texas, United States, 77043 | |
Plano, Texas, United States, 75093 | |
San Antonio, Texas, United States, 78209 | |
San Antonio, Texas, United States, 78229 | |
San Antonio, Texas, United States, 78240 | |
Webster, Texas, United States, 77598 |
Documents provided by Heron Therapeutics:
Responsible Party: | Heron Therapeutics |
ClinicalTrials.gov Identifier: | NCT03015532 |
Other Study ID Numbers: |
HTX-011-209 |
First Posted: | January 10, 2017 Key Record Dates |
Results First Posted: | October 27, 2021 |
Last Update Posted: | October 27, 2021 |
Last Verified: | September 2021 |
knee knee replacement arthroplasty joint replacement knee pain |
Pain, Postoperative Postoperative Complications Pathologic Processes Pain Neurologic Manifestations Bupivacaine Ropivacaine |
Anesthetics, Local Anesthetics Central Nervous System Depressants Physiological Effects of Drugs Sensory System Agents Peripheral Nervous System Agents |